GSK news

GlaxoSmithKline confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant.

GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced today a collaboration to develop macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.

GlaxoSmithKline and Genmab A/S today announced that the United States Food and Drug Administration (FDA) informed the companies that the agency has extended the action date for the ofatumumab BLA application by three months.

GlaxoSmithKline plc (GSK) today announced an agreement with Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) to develop and market selected products across an extensive number of emerging markets, excluding India.

The World Health Organisation (WHO) has announced it has raised the current level of influenza pandemic alert from phase 5 to phase 6.

GSK today announced it has entered into a definitive agreement to form a new Joint Venture with Shenzhen Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market.

New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria® (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing.

RECORD trial also demonstrates durable blood sugar control over time with Avandia

The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline Biologicals’ vaccine against rotavirus, Rotarix™.

GSK and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines.